J
Jan Budczies
Researcher at University Hospital Heidelberg
Publications - 185
Citations - 16222
Jan Budczies is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 48, co-authored 166 publications receiving 12762 citations. Previous affiliations of Jan Budczies include German Cancer Research Center & Humboldt University of Berlin.
Papers
More filters
Journal ArticleDOI
TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial
Marianne Sinn,Bruno Valentin Sinn,Denise Treue,U. Keilholz,Frederik Damm,Rosa Schmuck,Philipp Lohneis,Frederick Klauschen,Jana Käthe Striefler,Marcus Bahra,Hendrik Bläker,Sven Bischoff,Uwe Pelzer,Helmut Oettle,Hanno Riess,Jan Budczies,Jan Budczies,Carsten Denkert,Carsten Denkert +18 more
TL;DR: The sensitivity of TP53mut PDAC to gemcitabine in CONKO-001 provides a lead for further mechanistic investigations and a functional validation in The Cancer Genome Atlas (TCGA) sequencing data.
Journal ArticleDOI
An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
Balázs Győrffy,Lőrinc S. Pongor,Giulia Bottai,Xiaotong Li,Jan Budczies,András Szabó,Christos Hatzis,Lajos Pusztai,Libero Santarpia +8 more
TL;DR: These findings demonstrate that sequence alterations influence gene expression and oncogenic pathways, possibly affecting the outcome of breast cancer patients, and provide potential opportunities to identify non-coding variations with functional and clinical relevance in breast cancer.
Journal ArticleDOI
Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer.
Aurelia Noske,Sybille Lipka,Jan Budczies,Kathrin Müller,Christoph Loddenkemper,Heinz J. Buhr,Martin Kruschewski +6 more
TL;DR: The data suggest that the assessment of both p53 and p21 expression may provide prognostic information in colorectal cancer patients and this combination might be helpful to identify patients who could benefit from chemotherapy.
Journal ArticleDOI
Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue.
Bruno Valentin Sinn,Silvia Darb-Esfahani,Ralph M. Wirtz,Jan Budczies,Jalid Sehouli,Radoslav Chekerov,Manfred Dietel,Carsten Denkert +7 more
TL;DR: Sinn B V, Darb‐Esfahani S, Wirtz R M, Budczies J, Sehouli J, Chekerov R, Dietel M & Denkert C (2011) Histopathology 59, 918–927.
Journal ArticleDOI
Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma.
Jan Budczies,Jan Budczies,Martina Kirchner,Klaus Kluck,Klaus Kluck,Daniel Kazdal,Julia Glade,Michael Allgäuer,Mark Kriegsmann,CP Heußel,Felix J.F. Herth,Hauke Winter,Michael Meister,Thomas Muley,Torsten Goldmann,Stefan Fröhling,Martin Wermke,Cornelius F. Waller,Amanda Tufman,Martin Reck,Solange Peters,Peter Schirmacher,Peter Schirmacher,Michael Thomas,Petros Christopoulos,Albrecht Stenzinger,Albrecht Stenzinger +26 more
TL;DR: In this paper, a comparative mRNA expression profiling of 31 ALK-positive, 40 EGFR-positive and 43 ALK/EGFR-negative lung adenocarcinoma (ADC) focused on immune gene expression was performed.